TQB2922 clinical trials
How each study uses TQB2922 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the TQB2922 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. (3) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (2)
Often tested with
Tested in the same studies.
Trifluridine tipiracil drug combination (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test TQB2922.
- Dec 2026Clinical Trial of TQB2922 for Injection in Patients With Advanced CancersPhase 1 · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Aug 2027TQB2922 Injection Given Under the Skin With Chemotherapy as Initial Treatment for Colorectal Cancer That Has SpreadPhase 1/2 · Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Studies
Open first, then newest update. How each study uses TQB2922 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- TQB2922 Injection Given Under the Skin With Chemotherapy as Initial Treatment for Colorectal Cancer That Has SpreadNot yet recruitingPhase 1/2Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.NCT07844187Written as TQB2922 injection (subcutaneous administration)
- Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced CancersRecruitingPhase 1Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.NCT07260708Written as TQB2922 injection (subcutaneous injection)
- Treatment of Recurrent/Metastatic Head and Neck CancerNot yet recruitingPhase 1/2Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.NCT07601204Written as TQB2922 Subcutaneous Injection
- TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal CancerRecruitingPhase 1/2Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT07044908Written as TQB2922 injection ± TAS-102 tablets
- Clinical Trial of TQB2922 for Injection in Patients With Advanced CancersRecruitingPhase 1Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT06188624Written as TQB2922 for injection